Misleading and dangerous dyspeptic disorders
DOI:
https://doi.org/10.56294/hl2024.665Keywords:
ovarian cancer, nonspecific symptoms, dyspepsia, misdiagnosis, deathAbstract
Ovarian cancer is often fatal because it is usually advanced when diagnosed. It mainly affects perimenopausal and postmenopausal women. The average age at diagnosis is 63 years. The risk of ovarian cancer increases with a history of ovarian cancer in a first-degree relative, nulliparity, delayed childbearing, early menarche, delayed menopause, personal or family history of endometrial, breast or colon cancer. Most ovarian cancers develop from epithelial cells; the rest (germ cell tumors, sex cord stromal tumors) develop from other types of ovarian cells). Evaluation usually includes ultrasound, computed tomography or magnetic resonance imaging, biopsy and measurement of tumor markers. Treatment requires hysterectomy, bilateral salpingo-oophorectomy, chemotherapy, cytoreduction. Ovarian cancer may be asymptomatic or symptoms may be nonspecific (e.g. dyspepsia, early satiety, bloating, changes in bowel habits, urinary frequency) which may lead to misdiagnosis of other conditions and death of the patient.
References
1.RodríguezReigosa JE, Guerrero García LP, Esperón Noa RP, Linchenat Lambert A, Silveira Pablos JM, Díaz Ortega I, et al. Cáncer de ovario en el Instituto Nacional de Oncología y Radiobiología de Cuba: 2001 a 2005. Rev Cubana Cir. 2009 [citado 8 Feb 2012]; 48 (1). Disponible en: http://www.bvs.sld.cu/revistas/cir/vol48_1_09/cir08109.htm
MEDISAN 2012; 16(6): 930
2.Moreno Antunes A, HalibertoArmenteros B, Morán Piñero R, Anderson Croswel Ch. Diagnóstico y tratamiento quirúrgico del cáncer de ovario en el Hospital “Vladimir Ilich Lenin”. Correo Científico Médico de Holguín. 2008 [citado 15 May 2011]; 12 (3). Disponible en: http://www.cocmed.sld.cu/no123/pdf/n123ori7.pdf
3.Jiménez Hernández Y. Cáncer de ovario. Prevalencia, diagnóstico y tratamiento. http://www.portalesmedicos.com/publicaciones/articles/2258/1/Cancer-de-ovario-Prevalencia-diagnostico-y-tratamiento.html [consulta: 29 julio 2010].
4. M, Rosenberg H. Lecciones de anatomía patológica [citado 23 Agos 2011]. Disponible en: http://escuela.med.puc.cl/publ/anatomiapatologica/indice.
5 .National cancer institute's surveillance, epidemiology and end results program: cancer stat facts:ovariancáncer. Accessed july 14 2023.
6.KurnitKC, Fleming GF, Lengyel E: updates and new options in advanced epithelial ovarian cancer treatment. Obstetric gynecol 137(1): 108-121, 2021 do:10. 1097/ AOG000000000004173
7.Shi T, Zhu J, Feng Y, et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum sensitive relapsed ovarian cancer. Lancet oncol 22(4): 439- 449, 2021.
8. Zciros E, Lynam S, Attwood KM, et al: efficacy and safety ofpembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of ovarian cancer. JAMA oncol 78( 1): 78- 85, 2021.
9. Menon U, Gentry maharaj A, Burnell m, et al: ovarian cancer population screening and mortality after long term follow- up in the uk collaborative trial of ovarian cancer screening: a randomized control trial. Lancet 397( 10290):2182- 2193, 2021.
10. Coleman RL, Fleming GF, Brady MF, et al :veliparib with first- line chemotherapy as a maintenance therapy in ovarian cancer.NEngl J Med 381(25): 2483- 2485, 2019.
Published
Issue
Section
License
Copyright (c) 2024 José González Molina , Rosibery Samón Marrero , Yanila Savon Robert (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
